(MENAFN- Straits Research)
Transcriptomics Market Size
The global transcriptomics market size was valued at USD 8.2 billion in 2025 and is projected to grow from USD 8.63 billion in 2026 to USD 12.97 billion by 2034, registering a CAGR of 5.23% during the forecast period from 2026 to 2034. North America dominated the transcriptomics market with a market share of 42.3% in 2025.
Transcriptomics is the study and analysis of an organism's complete set of RNA transcripts to understand gene expression, regulation, and cellular activity under specific biological conditions. It uses technologies such as RNA sequencing and microarrays to identify and measure RNA molecules. Transcriptomics is widely used in disease research, drug discovery, precision medicine, biotechnology, and molecular biology to identify biomarkers, understand biological mechanisms, and support the development of targeted therapies.
Transcriptomics Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 8.2 Billion
2026 Market Size: USD 8.63 Billion
2034 Projected Market Size: USD 12.97 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 5.23%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.3%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 15.4%
Segment Insights
By Type
Leading Segment: Consumables
Market Share in 2025: 45.8%
By Technology
Fastest-Growing Segment: Next-Generation Sequencing (NGS)
CAGR: 14.8% (2026–2034)
By Applications
Leading Segment: Drug Discovery and Development
Market Share in 2025: 43.5%
By End User
Fastest-Growing Segment: Biotechnology Companies
CAGR: 15.2% (2026–2034)
Download a Free Sample To learn more about this report,
Transcriptomics Market Trends
Growing Adoption of Spatial Transcriptomics for High-Resolution Biological Analysis
The transcriptomics market is increasingly shifting toward spatial transcriptomics, enabling researchers to analyze gene expression while preserving the spatial location of cells within tissue. The technology is gaining traction in oncology, neuroscience, immunology, developmental biology, and drug discovery because it can reveal cellular interactions, tissue architecture, and disease mechanisms that conventional transcriptomics may not capture. This trend is supporting transcriptomics market growth as research organizations and biopharmaceutical companies seek higher-resolution and more comprehensive biological insights.
In June 2026, Illumina launched the StrataMap Spatial Solution, an end-to-end sequencing-based spatial transcriptomics platform offering single-cell resolution and unbiased whole-transcriptome profiling across a large tissue capture area. The solution is designed to support applications including tumor mapping, tissue development, and drug-target discovery.
Increasing Integration of AI and Multiomics in Transcriptomic Data Analysis
Another important trend is the increasing integration of artificial intelligence, machine learning, and multiomics into transcriptomics workflows. Advanced computational tools are helping researchers analyze large and complex transcriptomic datasets, improve cell segmentation, identify biological patterns, and combine RNA data with genomic, proteomic, and tissue-imaging information. This development is supporting transcriptomics market growth by improving the depth and interpretability of biological research while making large-scale studies more practical.
In April 2026, Vizgen introduced new AI-powered cell segmentation options and expanded gene-panel capabilities for its MERSCOPE and MERSCOPE Ultra platforms. The updates were designed to streamline spatial transcriptomics workflows and improve downstream analysis of high-resolution biological data.
Transcriptomics Market Dynamics
Market Drivers
Growing Demand for Detailed Gene Expression Analysis
Transcriptomics is becoming increasingly important for understanding how genes are expressed, how cells respond to disease, and how biological processes change under different conditions. RNA sequencing can measure the types and quantities of RNA molecules present in a sample, providing researchers with information that cannot be obtained from genome sequence data alone. This is strengthening transcriptomics market demand across drug discovery, cancer research, precision medicine, developmental biology, and biomarker studies. The increasing availability of sequencing technologies and computational tools is also making transcriptome analysis more practical across research settings.
In June 2026, the U.S. National Institutes of Health expanded its All of Us Research Program with RNA-sequencing data from nearly 9,000 participants, adding transcriptomic information to one of the world's largest integrated genomic and health datasets.
Market Restraints
Complexity of Data Generation and Interpretation
Transcriptomic workflows generate large and complex datasets that require specialized sequencing infrastructure, bioinformatics expertise, computational resources, and appropriate analytical pipelines. Researchers must also manage sample quality, sequencing depth, normalization, data storage, and interpretation to obtain reliable biological conclusions. These requirements influence transcriptomics market analysis because laboratories adopting advanced transcriptomic approaches may need additional equipment, software, skilled personnel, and data-management capabilities. Differences between sample types and experimental workflows can further complicate comparisons and reproducibility, particularly when researchers combine data generated using different sequencing technologies or analytical methods.
In March 2026, researchers published a scalable single-cell total RNA sequencing approach designed to capture both coding and noncoding RNA, illustrating the technical complexity involved in obtaining broader transcriptomic information at single-cell resolution.
Market Opportunities
Expansion of Single-Cell and Multiomic Transcriptomics
Single-cell and multiomic approaches are creating opportunities to study gene activity at much greater biological resolution. Instead of averaging RNA expression across large groups of cells, single-cell transcriptomics can reveal differences between individual cell populations and help researchers investigate cellular heterogeneity in tumors, tissues, and disease states. Combining transcriptomic data with genomic, proteomic, or other molecular information can provide a more comprehensive view of biological systems. These developments are shaping transcriptomics market trends toward integrated, high-resolution approaches that can support drug discovery, biomarker identification, and precision medicine.
In June 2026, NIH's All of Us Research Program entered a broader multiomic phase by combining genomic data with proteomics and RNA-sequencing data, demonstrating the growing use of integrated molecular datasets in biomedical research.
Market Challenges
Improving RNA Characterization Across Complex Biological Systems
A major challenge is obtaining comprehensive and accurate information about the full range of RNA molecules, including their sequences, modifications, structures, locations, interactions, and functions. Conventional approaches may capture only selected aspects of RNA biology, while emerging applications require more sophisticated experimental and computational technologies. This remains an important consideration for the transcriptomics market report because researchers increasingly need methods capable of resolving complex RNA behavior across different cells and tissues. Improving sensitivity, accuracy, scalability, and standardization will be essential for expanding transcriptomic research into more advanced biological and clinical applications.
In August 2026, the NIH Common Fund announced plans for its RNomics program to develop technologies and resources for integrated characterization of RNA sequences, modifications, structures, locations, interactions, and functions, highlighting the industry's continuing technological challenges.
Transcriptomics Market Segmentation Analysis
By Type
Consumables Segment Dominated the Market with 45.8% Share in 2025
The consumables segment dominated the global transcriptomics market with a 45.8% market share in 2025, valued at USD 3.76 billion. Its leading position is supported by the recurring need for reagents, assay components, sequencing materials, sample preparation products, and other consumable inputs used throughout transcriptomic workflows. Growing research activity and the increasing use of high-throughput molecular analysis are contributing to sustained demand for these products.
Instruments and software & services continue to support transcriptomics workflows by enabling sample processing, sequencing, data analysis, and interpretation. Their adoption is expanding as laboratories and research organizations incorporate increasingly sophisticated transcriptomic techniques into their research programs.
Request Customization to receive a tailored report.
By Technology
Next-Generation Sequencing (NGS) Segment Dominated the Market with 46.9% Share in 2025
The next-generation sequencing segment dominated the global transcriptomics market with a 46.9% market share in 2025, valued at USD 3.85 billion. NGS supports high-throughput analysis of RNA and gene expression, making it an important technology for transcriptome profiling and molecular research. Its ability to analyze large volumes of genetic information efficiently is supporting continued adoption across research, drug development, and disease-related studies.
Polymerase chain reaction, microarray, and other technologies continue to serve specialized transcriptomic research requirements. These approaches remain relevant for targeted analysis, gene expression studies, validation, and applications where specific analytical workflows are preferred.
By Applications
Diagnostics and Disease Profiling Segment is Projected to Register the Fastest Growth at a CAGR of 14.6%
The diagnostics and disease profiling segment is projected to register the fastest growth at a CAGR of 14.6% during the forecast period. Increasing use of transcriptomic analysis to investigate disease mechanisms, identify molecular signatures, and improve understanding of patient biology is supporting demand in this area. Advances in sequencing and computational analysis are further enabling researchers to examine gene-expression patterns associated with different diseases.
Drug discovery and development remains a major application area, as transcriptomic data can help researchers understand biological pathways, identify potential therapeutic targets, and evaluate molecular responses to treatments. Other applications also contribute to market expansion across diverse biological research activities.
By End User
Biotechnology Companies Segment is Projected to Register the Fastest Growth at a CAGR of 15.2%
The biotechnology companies segment is projected to register the fastest growth at a CAGR of 15.2% during the forecast period. Biotechnology firms are increasingly applying transcriptomics to biomarker discovery, therapeutic research, molecular characterization, and development of innovative biological products. The growing integration of sequencing and computational technologies is expanding the ability of these companies to generate and interpret complex gene-expression data.
Academic and research institutes remain a major end-user group, supported by extensive use of transcriptomics in basic biological research and disease studies. Pharmaceutical companies also continue to adopt transcriptomic approaches to support drug discovery, development, target identification, and investigation of treatment responses.
Speak to an Analyst to discuss market opportunities.
Transcriptomics Market Regional Outlook
North America Transcriptomics Market Analysis
The North American transcriptomics market accounted for 42.3% of the global market, reaching USD 3.47 billion in 2025, and is projected to grow at a CAGR of 11.8% during the forecast period. The region's leading position is supported by advanced genomics research infrastructure, strong biotechnology and pharmaceutical industries, increasing investments in molecular research, and growing adoption of transcriptomic technologies for drug discovery, precision medicine, and disease research.
United States Transcriptomics Market Insights
The United States represents a major market in North America. Its strong biotechnology ecosystem, extensive genomics research activities, advanced sequencing capabilities, and substantial pharmaceutical R&D investments continue to support transcriptomics market growth.
Canada Transcriptomics Market Insights
Canada's established life sciences sector, growing genomics research capabilities, and increasing adoption of advanced molecular analysis technologies continue to support regional market development.
Unlock Regional Insights to access country-level data, & regional trends.
Asia Pacific Transcriptomics Market Analysis
The Asia Pacific transcriptomics market accounted for 22.7% of the global market, reaching USD 1.86 billion in 2025, and is projected to grow at a CAGR of 15.4% during the forecast period. The region records the fastest growth among the listed markets, driven by expanding biotechnology industries, increasing healthcare investments, growing genomics research, and rising adoption of advanced sequencing and molecular analysis technologies.
China Transcriptomics Market Insights
China represents a major market within the Asia Pacific. Expanding biotechnology and pharmaceutical R&D, increasing genomics research, and growing investments in advanced sequencing technologies continue to support transcriptomics market growth.
Japan Transcriptomics Market Insights
Japan's advanced life sciences ecosystem, strong biomedical research capabilities, and increasing adoption of molecular analysis technologies continue to support demand for transcriptomics solutions.
India Transcriptomics Market Insights
India's expanding biotechnology sector, growing genomics research capabilities, and increasing adoption of advanced molecular diagnostics continue to create opportunities for transcriptomics market development.
Europe Transcriptomics Market Analysis
Europe's transcriptomics market accounted for 26.4% of the global market, reaching USD 2.16 billion in 2025, and is expected to register a CAGR of 12.1% during the forecast period. The region's growth is supported by increasing investments in genomics and biotechnology research, expanding precision medicine initiatives, and growing adoption of advanced sequencing and transcriptomic analysis technologies.
Germany Transcriptomics Market Insights
Germany represents a major European market. Its strong pharmaceutical and biotechnology industries, advanced research infrastructure, and growing focus on molecular diagnostics and precision medicine continue to support transcriptomics adoption.
United Kingdom Transcriptomics Market Insights
The United Kingdom's established genomics research ecosystem, pharmaceutical R&D capabilities, and increasing focus on personalized healthcare continue to create opportunities for transcriptomics technologies.
Latin America Transcriptomics Market Analysis
Latin America's transcriptomics market accounted for 5.1% of the global market, reaching USD 0.42 billion in 2025, and is expected to grow at a CAGR of 10.6% during the forecast period. Increasing investments in healthcare and biotechnology, expanding genomics research, and growing adoption of molecular analysis technologies continue to support regional market development.
Brazil Transcriptomics Market Insights
Brazil represents a major regional market. Its expanding biotechnology and biomedical research sectors, increasing genomics activities, and growing adoption of advanced sequencing technologies continue to support transcriptomics market growth.
Middle East & Africa Transcriptomics Market Analysis
The Middle East & Africa transcriptomics market accounted for 3.5% of the global market, reaching USD 0.29 billion in 2025, and is anticipated to grow at a CAGR of 9.8% during the forecast period. Healthcare infrastructure development, increasing investments in biotechnology and genomics, and growing adoption of advanced molecular technologies continue to support regional market expansion.
UAE Transcriptomics Market Insights
The UAE's investments in advanced healthcare, biotechnology, and genomics research continue to support demand for transcriptomics technologies.
Saudi Arabia Transcriptomics Market Insights
Saudi Arabia's healthcare modernization, growing life sciences ecosystem, and increasing focus on genomic medicine continue to create opportunities for transcriptomics market development.
Transcriptomics Market Competitive Landscape
The global transcriptomics market is highly competitive, with leading life sciences, genomics, sequencing, molecular biology, and biotechnology companies competing through RNA sequencing, microarray technologies, single-cell transcriptomics, spatial transcriptomics, library preparation, bioinformatics, and gene expression analysis solutions. The major players in the market include Pacific Biosciences of California Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., QIAGEN, Bio-Rad Laboratories Inc., Takara Bio Inc., PerkinElmer Inc., Fluidigm Corporation, F. Hoffmann-La Roche, Merck & Co. Inc., Promega Corporation, RNA Connect, Becton, Dickinson and Company, Bio-Techne Corporation, and others.
Industry participants are focusing on developing high-throughput and high-resolution transcriptomic technologies that enable researchers to analyze gene expression, RNA modifications, cellular heterogeneity, and molecular pathways with greater sensitivity and accuracy. Companies are investing in next-generation sequencing, single-cell RNA sequencing, spatial transcriptomics, long-read sequencing, advanced sample preparation, and bioinformatics platforms to expand transcriptomic research capabilities. Growing demand for precision medicine, cancer research, biomarker discovery, drug development, and personalized therapeutics is encouraging pharmaceutical companies, research institutions, and biotechnology organizations to adopt advanced transcriptomics technologies.
Illumina Inc.: An Emerging Market Leader
Illumina Inc. is one of the leading companies in the global transcriptomics market, providing next-generation sequencing platforms, consumables, library preparation technologies, and informatics solutions that enable researchers to perform comprehensive RNA sequencing and gene expression analysis. Its sequencing technologies support applications including bulk RNA sequencing, single-cell analysis, transcriptome profiling, and other genomic research workflows.
In 2026, Illumina continued strengthening its RNA sequencing and transcriptomics technology portfolio, with emphasis on high-throughput sequencing, improved sequencing accuracy, and integrated genomic analysis workflows. The company continued advancing sequencing technologies that enable researchers to characterize transcriptomes at greater scale and resolution, supporting applications in cancer research, drug discovery, biomarker development, and precision medicine. These advancements reinforce Illumina's competitive position in the global transcriptomics market.
List of Key and Emerging Players in Transcriptomics Market
Pacific Biosciences of California Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Illumina Inc.
QIAGEN
Bio-Rad Laboratories Inc.
Takara Bio Inc.
PerkinElmer Inc.
Fluidigm Corporation
F-Hoffmann La-Roche
Merck & Co. Inc
Promega Corporation
RNA Connect
Becton, Dickinson and Company
Bio-Techne Corporation
Others
Key Industry Developments
June 2026: Illumina launched an expanded single-cell and spatial transcriptomics workflow, integrating next-generation sequencing with advanced bioinformatics to improve gene expression analysis for translational and clinical research.
April 2026: 10x Genomics introduced the latest version of its Visium HD Spatial Gene Expression platform, providing higher-resolution transcriptomic profiling to support oncology, neuroscience, and biomarker discovery research.
January 2026: Bruker Corporation completed the acquisition of NanoString Technologies, strengthening its spatial biology and transcriptomics portfolio by combining NanoString's molecular profiling technologies with Bruker's life science instrumentation.
October 2025: Standard BioTools Inc. (formerly Fluidigm) launched new high-plex transcriptomics workflows integrating advanced single-cell analysis and multi-omics capabilities for life science research.
Report Scope
Comments
No comment